Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free VRAYQ Stock Alerts

ViewRay (VRAYQ) Competitors

Compare

VRAYQ vs. SDCCQ, GMVDF, TTOO, AFIB, and UTRS

Should you buy ViewRay stock or one of its competitors? MarketBeat compares ViewRay with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ViewRay include SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), T2 Biosystems (TTOO), Acutus Medical (AFIB), and Minerva Surgical (UTRS). These companies are all part of the "medical equipment" industry.

How does ViewRay compare to SmileDirectClub?

ViewRay (NASDAQ:VRAYQ) and SmileDirectClub (NASDAQ:SDCCQ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 0.1% of SmileDirectClub shares are owned by institutional investors. 2.5% of ViewRay shares are owned by company insiders. Comparatively, 64.7% of SmileDirectClub shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ViewRay has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, SmileDirectClub has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

In the previous week, ViewRay had 1 more articles in the media than SmileDirectClub. MarketBeat recorded 1 mentions for ViewRay and 0 mentions for SmileDirectClub. ViewRay's average media sentiment score of 0.00 equaled SmileDirectClub'saverage media sentiment score.

Company Overall Sentiment
ViewRay Neutral
SmileDirectClub Neutral

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
SmileDirectClub N/A N/A N/A

SmileDirectClub has higher revenue and earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33M-$0.31N/A
SmileDirectClub$470.74M0.00-$86.40M-$0.29N/A

Summary

SmileDirectClub beats ViewRay on 5 of the 8 factors compared between the two stocks.

How does ViewRay compare to G Medical Innovations?

G Medical Innovations (NASDAQ:GMVDF) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, ViewRay had 1 more articles in the media than G Medical Innovations. MarketBeat recorded 1 mentions for ViewRay and 0 mentions for G Medical Innovations. G Medical Innovations' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
G Medical Innovations Neutral
ViewRay Neutral

Company Net Margins Return on Equity Return on Assets
G Medical InnovationsN/A N/A N/A
ViewRay N/A N/A N/A

G Medical Innovations has a beta of 27.28, meaning that its stock price is 2,628% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

6.0% of G Medical Innovations shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 37.1% of G Medical Innovations shares are owned by company insiders. Comparatively, 2.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

G Medical Innovations has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G Medical Innovations$4.42M0.00-$24.63MN/AN/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Summary

G Medical Innovations and ViewRay tied by winning 3 of the 6 factors compared between the two stocks.

How does ViewRay compare to T2 Biosystems?

T2 Biosystems (NASDAQ:TTOO) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, ViewRay had 1 more articles in the media than T2 Biosystems. MarketBeat recorded 1 mentions for ViewRay and 0 mentions for T2 Biosystems. T2 Biosystems' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
ViewRay Neutral

T2 Biosystems has a beta of 7.71, meaning that its share price is 671% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

23.2% of T2 Biosystems shares are held by institutional investors. Comparatively, 15.5% of ViewRay shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by company insiders. Comparatively, 2.5% of ViewRay shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
ViewRay N/A N/A N/A

T2 Biosystems has higher earnings, but lower revenue than ViewRay. T2 Biosystems is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.01-$50.08M-$3.89N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Summary

ViewRay beats T2 Biosystems on 7 of the 10 factors compared between the two stocks.

How does ViewRay compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

56.9% of Acutus Medical shares are held by institutional investors. Comparatively, 15.5% of ViewRay shares are held by institutional investors. 5.2% of Acutus Medical shares are held by insiders. Comparatively, 2.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Acutus Medical has higher earnings, but lower revenue than ViewRay. Acutus Medical is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

In the previous week, ViewRay had 1 more articles in the media than Acutus Medical. MarketBeat recorded 1 mentions for ViewRay and 0 mentions for Acutus Medical. Acutus Medical's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
ViewRay Neutral

ViewRay has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ViewRay's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
ViewRay N/A N/A N/A

Acutus Medical has a beta of 5.67, meaning that its stock price is 467% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Summary

ViewRay beats Acutus Medical on 6 of the 11 factors compared between the two stocks.

How does ViewRay compare to Minerva Surgical?

Minerva Surgical (NASDAQ:UTRS) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

15.5% of ViewRay shares are held by institutional investors. 8.5% of Minerva Surgical shares are held by company insiders. Comparatively, 2.5% of ViewRay shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Minerva Surgical has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

In the previous week, ViewRay had 1 more articles in the media than Minerva Surgical. MarketBeat recorded 1 mentions for ViewRay and 0 mentions for Minerva Surgical. Minerva Surgical's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Minerva Surgical Neutral
ViewRay Neutral

Minerva Surgical has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Company Net Margins Return on Equity Return on Assets
Minerva SurgicalN/A N/A N/A
ViewRay N/A N/A N/A

Summary

Minerva Surgical and ViewRay tied by winning 4 of the 8 factors compared between the two stocks.

Get ViewRay News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAYQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAYQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAYQ vs. The Competition

Export
MetricViewRayElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$18K$80.63M$7.16B$12.48B
Dividend YieldN/AN/A2.66%6.52%
P/E Ratio0.0010.1028.0224.70
Price / SalesN/A192.41540.5599.42
Price / CashN/A41.3649.2657.09
Price / BookN/A5.5710.966.46
Net Income-$107.33M-$5.50M$3.57B$337.01M

ViewRay Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAYQ
ViewRay
N/AN/AN/AN/A$18K$102.21MN/A300
SDCCQ
SmileDirectClub
N/AN/AN/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/AN/AN/AN/A$26K$4.42MN/A72
TTOO
T2 Biosystems
N/A$0.00
+20.0%		N/A-98.6%$13K$7.68MN/A180
AFIB
Acutus Medical
N/AN/AN/AN/A$3K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRAYQ) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel